Generic Name:
triheptanoin
Project Status:
Active
Therapeutic Area:
Long-chain fatty acid oxidation disorders
Manufacturer:
Ultragenyx Canada Inc
Call for patient/clinician input open:
Brand Name:
Dojolvi
Project Line:
Reimbursement Review
Project Number:
SR0684-000
Call for patient/clinician input closed:
Details
Manufacturer Requested Reimbursement Criteria1:
Ultragenyx is requesting triheptanoin be reimbursed for the treatment of adult and pediatric patients with long-chain fatty acid oxidation disorders (LC-FAOD)
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Dojolvi (triheptanoin) is indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with long-chain fatty acid oxidation disorders (LC-FAOD).
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.